[go: up one dir, main page]

CA2137363A1 - Use of Zona Pellucida Glycoproteins for Immunocontraception - Google Patents

Use of Zona Pellucida Glycoproteins for Immunocontraception

Info

Publication number
CA2137363A1
CA2137363A1 CA 2137363 CA2137363A CA2137363A1 CA 2137363 A1 CA2137363 A1 CA 2137363A1 CA 2137363 CA2137363 CA 2137363 CA 2137363 A CA2137363 A CA 2137363A CA 2137363 A1 CA2137363 A1 CA 2137363A1
Authority
CA
Canada
Prior art keywords
zona pellucida
vaccine
immunocontraception
delivery system
liposome delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA 2137363
Other languages
French (fr)
Other versions
CA2137363C (en
Inventor
Robert Brown
Warwick Kimmins
Michael Mezei
Bill Pohajdak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunovaccine Technologies Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2137363A1 publication Critical patent/CA2137363A1/en
Application granted granted Critical
Publication of CA2137363C publication Critical patent/CA2137363C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0006—Contraceptive vaccins; Vaccines against sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Dispersion Chemistry (AREA)
  • Reproductive Health (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

A vaccine for the immunocontraception of mammals is described. The vaccine consists of zona pellucida antigens and an adjuvant encapsulated in a liposome delivery system. The liposome delivery system allows for the slow release of antigen resulting in a prolonged immune response. In particular, after a single injection of the vaccine, levels of anti-zona pellucida antibodies were detected for up to 22 months. Thus, the vaccine according to the present invention is effective after a single dose and is therefore very useful in immunocontraceptive protocols.
CA002137363A 1992-06-05 1993-06-07 Use of zona pellucida glycoproteins for immunocontraception Expired - Fee Related CA2137363C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89280792A 1992-06-05 1992-06-05
US892,807 1992-06-05
PCT/CA1993/000239 WO1993025231A1 (en) 1992-06-05 1993-06-07 Use of zona pellucida glycoproteins for immunocontraception

Publications (2)

Publication Number Publication Date
CA2137363A1 true CA2137363A1 (en) 1993-12-23
CA2137363C CA2137363C (en) 1999-06-15

Family

ID=25400523

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002137363A Expired - Fee Related CA2137363C (en) 1992-06-05 1993-06-07 Use of zona pellucida glycoproteins for immunocontraception

Country Status (3)

Country Link
AU (1) AU4303493A (en)
CA (1) CA2137363C (en)
WO (1) WO1993025231A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925142B2 (en) 2005-10-07 2018-03-27 Immunovaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase as a vehicle for cancer treatment
US11077184B2 (en) 2011-10-06 2021-08-03 Immunovaccine Technologies Inc. Liposome compositions comprising PAM2Cys or PAM3Cys adjuvant and methods for inducing a humoral immune response
US11235069B2 (en) 2007-09-27 2022-02-01 Immunovaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
US11717563B2 (en) 2008-06-05 2023-08-08 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1140151A2 (en) * 1998-12-22 2001-10-10 Dalhousie University Compositions and methods for reducing or preventing fertilization in fish and birds
AU5909500A (en) * 1999-07-01 2001-01-22 University Of Georgia Research Foundation, Inc., The Method and composition for affecting reproductive systems
AU5781300A (en) * 1999-07-01 2001-01-22 University Of Georgia Research Foundation, Inc., The Fertility impairing vaccine containing avian zona pellucida protein and method of use
WO2002038175A1 (en) 2000-11-07 2002-05-16 Immunovaccine Technologies Inc. Vaccines with enhanced immune response and methods for their preparation
BRPI0919174B1 (en) 2008-09-17 2020-11-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention recombinant rabies virus, immunogenic composition and its use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1504259A (en) * 1976-07-19 1978-03-15 Merck & Co Inc Immunological control of fertility
US4996297A (en) * 1987-10-07 1991-02-26 Zonagen, Inc. Recombinantly expressed rabbit zona pellucida polypeptides

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925142B2 (en) 2005-10-07 2018-03-27 Immunovaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase as a vehicle for cancer treatment
US11235069B2 (en) 2007-09-27 2022-02-01 Immunovaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
US11717563B2 (en) 2008-06-05 2023-08-08 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
US11077184B2 (en) 2011-10-06 2021-08-03 Immunovaccine Technologies Inc. Liposome compositions comprising PAM2Cys or PAM3Cys adjuvant and methods for inducing a humoral immune response

Also Published As

Publication number Publication date
AU4303493A (en) 1994-01-04
WO1993025231A1 (en) 1993-12-23
CA2137363C (en) 1999-06-15

Similar Documents

Publication Publication Date Title
AU7980794A (en) Methods and compositions for microencapsulation of antigens for use as vaccines
EP0955059A3 (en) Vaccines containing a saponin and a sterol
CA2136429A1 (en) Combined vaccines comprising hepatitis b surface antigen and other antigens
CA2172507A1 (en) Methods and compositions for microencapsulation of antigens for use as vaccines
CA2123580A1 (en) Antigen of hybrid m protein and carrier for group a streptococcal vaccine
CA2183435A1 (en) Vaccines containing paucilamellar lipid vesicles as immunological adjuvants
CA2132833A1 (en) Hepatitis vaccines containing 3-o-deacylated monophosphoryl lipid a
MY111829A (en) Modified live brsv vaccine
CA2132547A1 (en) Vaccines Containing Non-Ionic Surfactant Vesicles
CA2143823A1 (en) Retro-, inverso - and retro-inverso synthetic peptide analogues
NZ323973A (en) Vaccine compositions for intranasal administration comprising chitosan and use thereof
EP0017557A3 (en) Liposome particle containing viral or bacterial antigenic subunit and process for preparation
AU4188100A (en) Dry formulation for transcutaneous immunization
CA2086094A1 (en) Vaccine compositions containing liposomes
CA2137363A1 (en) Use of Zona Pellucida Glycoproteins for Immunocontraception
WO1999050303A3 (en) Immune response modulator alpha-2 macroglobulin complex
CA2098533A1 (en) Carrier system against gnrh
EP0423315A4 (en) Dendritic polymer of multiple antigen peptide system useful as anti-malarial vaccine
AU1217395A (en) Immunological response potentiation process
EP0888777A3 (en) Recombinant bovine herpesvirus type 1 polyptpetides and vaccines
AU2458888A (en) Vaccine adjuvant
GEP20053446B (en) Adjuvant Combination Formulations
MX9604185A (en) An adjuvanted vaccine which is substantially free of non-host albumin.
GB9506863D0 (en) Vaccines
CA2133108A1 (en) Pasteurella haemolytica type a-1 bacterin-toxoid vaccine

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed